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ABSTRAK
Latar belakang: perlemakan hati non-alkoholik (PHNA) berhubungan dengan berbagai penyakit metabolik. 
Penelitian terbaru menunjukkan peranan asam urat pada PHNA melalui proses oksidatif dan inflamasi. Laporan 
ini bertujuan mengevaluasi hubungan antara kadar asam urat serum dengan PHNA. Metode: tinjauan pustaka 
sistematik dilakukan dengan menggunakan Pubmed dan Cochrane library. Kualitas dari setiap studi dikaji 
dengan menggunakan the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). 
Semua data dianalisis dengan menggunakan REVIEW MANAGER 5.3. Hasil: didapatkan 11 studi dari Amerika 
dan Asia yang secara keseluruhan melibatkan 100.275 subjek. Pooled adjusted OR untuk NAFLD adalah 1,92 
(95% CI: 1,66-2,23; p<0,00001). Analisis subgroup dilakukan berdasarkan desain studi, gender, subjek non 
diabetes, subjek non obese. Semua analisa subgroup menunjukkan adjusted OR yang bermakna secara statistic 
dan heterogenitas yang rendah hingga sedang pada mayoritas analisis subgrup. Dua studi menunjukkan 
hubungan antara kenaikan serum asam urat dengan tingkat keparahan PHNA. Bias publikasi tidak ditemukan 
pada laporan ini. Kesimpulan: laporan ini menunjukkan hubungan antara kadar serum asam urat dengan PHNA. 
Temuan ini dapat memberikan pandangan yang baru terhadap asam urat dalam praktik klinis. Peningkatan 
kadar serum asam urat dapat menjadi pemicu bagi dokter untuk melakukan skrining PHNA.
Kata kunci: asam urat, perlemakan hati non-alkoholik, meta-analisis.
ABSTRACT
Background: non-alcoholic fatty liver disease (NAFLD) is known to be associated with some metabolic 
disorders. Recent studies suggested the role of uric acid in NAFLD through oxidative stress and inflammatory 
process. This study is aimed to evaluate the association between serum uric acid and NAFLD. Methods: a 
systematic literature review was conducted using Pubmed and Cochrane library. The quality of all studies 
was assessed using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). All 
data were analyzed using REVIEW MANAGER 5.3. Results: eleven studies from America and Asia involving 
100,275 subjects were included. The pooled adjusted OR for NAFLD was 1.92 (95% CI: 1.66-2.23; p<0.00001). 
Subgroup analyses were done based on study design, gender, non-diabetic subjects, non-obese subjects. All 
subgroup analyses showed statistically significant adjusted OR and most of which having low to moderate 
heterogeneity. Two studies revealed relationship between increased serum uric acid levels and severity of NAFLD. 
No publication bias was observed. Conclusion: our study demonstrated association between serum uric acid 
Vol 49 • Number 2 • April 2017                  Association between serum uric acid and non-alcoholic fatty liver disease
137
level and NAFLD. This finding brings a new insight of uric acid in clinical practice. Increased in serum uric 
acid levels might serve as a trigger for physician to screen for NAFLD.
Keywords: uric acid, non-alcoholic fatty liver disease, meta-analysis.
INTRODUCTION
Non alcoholic fatty liver disease (NAFLD) is 
one of the most common chronic liver diseases. 
The prevalence of NAFLD has doubled during 
last 20 years, ranging from 24% to 42% in 
Western countries and 5% to 30% in Asian 
countries, depending on the studied population.1-5 
NAFLD is diagnosed when daily alcohol 
consumption is ≤20 g/day in women and ≤30 g/
day in men and exclude other causes of disease 
(autoimmune, viral, steatogenic drugs, etc).4,5 
It is pathologically characterized by excessive 
accumulation of triglyceride (more than 5%) in 
the hepatocytes, ranging from simple steatosis, 
non alcoholic steatohepatitis (NASH), fibrosis, 
and liver cirrhosis which may progress to 
hepatocellular carcinoma (HCC). Multiple “hits”, 
having metabolic syndrome as a major role 
and inflammation process involving cytokines, 
adipokines, oxidative stress are hypothesized to 
explain the complex pathogenesis and progression 
of NAFLD.3,4 NAFLD, widely considered as 
liver manifestation of metabolic syndrome, is 
associated with some clinical conditions. Obesity, 
hypertension, diabetes, dyslipidemia are the most 
reviewed factors associated with NAFLD.4,6,7
Uric acid, the final oxidation product of 
purine metabolism in humans, is allied with 
metabolic disorders. It is widely known that 
increased serum uric acid levels often co-
exist with insulin resistance, atherosclerosis, 
hypertension, and obesity. Inflammation and 
oxidative stress are hypothesized to be the 
essential link in this relationship.8,9 Moreover, 
there is an increasing of evidence that uric acid 
relates with NAFLD. Petta, et al.10 showed 
hyperuricemia related with the severity of liver 
damage. Recently, many observational studies 
were done to explore the correlation between 
serum uric acid level and NAFLD.9,11-25
Therefore, we performed a meta-analysis 
study to evaluate the association between serum 
uric acid levels and NAFLD in adult.
METHODS
We conducted this study according to the 
meta-analysis PRISMA guideline (see PRISMA 
checklist).26 We did systematic literature search 
using Cochrane and PubMed database (up to 
December 2015). The following search terms 
were used for searching relevant literature 
with research subjects limited to humans and 
adult:“uric acid” OR“serum uric acid” OR 
“hyperuricemia”AND “non-alcoholic fatty liver 
disease” OR “NAFLD” OR “non-alcoholic 
steatohepatitis” OR “NASH” OR “fatty liver” 
OR “liver steatosis” AND “observational study” 
OR “cross sectional” OR “prospective study” 
OR “retrospective study”. Additional manual 
search was performed to look for additional 
relevant studies. Article selection and assessment 
were done by reviewers. We contacted the 
correspondence authors via email to obtain the 
required information when relevant information 
was not available in the published article.
Eligibility Criteria
The inclusion criteria were: (i) published 
observational studies with large sample size 
(more than 1000 subjects); (ii) study providing 
SUA and NAFLD risk factors; (iii) the outcome 
was NAFLD; (iv) the diagnostic criteria of 
outcome was clearly defined; (v) study had 
adjusted odds ratio (OR) with 95% confidence 
interval (CI) for NAFLD risk comparing the 
highest to lowest SUA. For studies with data 
published more than once or using the same 
subjects, only the article with larger number of 
subjects and adequate study strategy was chosen. 
Data Extraction
Data were extracted independently by 
authors from original studies as follows: author’s 
name, publication year; origin country, study 
design, participant characteristics (total number, 
gender, and age); category of SUA levels, 
NAFLD definition, incidence or prevalence of 
NAFLD, adjusted OR with 95% CI.
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Quality Assessment
We assessed the quality of each selected study 
by scoring 22-item Strengthening the Reporting 
of Observational Studies in Epidemiology 
(STROBE). The quality levels then were graded 
as good, fair, and poor. Only studies with good 
quality were included in our final analysis review. 
Discrepancies and disagreements were resolved 
by consensus.
Statistical Analysis
We used the fully adjusted OR with 95% 
CI and pooled it. The Mantel-Haenszel method 
was used to weight the studies included. A fixed-
effect model approach was use if there was no 
heterogeneity; otherwise, a random-effect model 
was used. Heterogeneity was assessed using I2. 
Negative value of I2 was put equal to 0. I2 values 
ranged from 0% (no observed heterogeneity) to 
100%, and interpreted according to Cochrane 
Consumers and Communication Review Group.
For subgroup analyses, we grouped the studies 
based on study design, gender, non-diabetic 
subjects, non-obese subjects and pooled the fully 
adjusted OR with 95% CI. Publication bias was 
assessed by funnel plot. Statistical analysis was 
performed using Review Manager 5.3.
RESULTS
Our initial search yielded 53 studies. 
After the final screening, 11 studies met our 
criteria.9,14-17,19-23,25 Within the 11 studies, one 
study by Wu, et. al. consisted of 2 sub studies 
with different subjects, place, and study designs 
(cross-sectional and longitudinal study). We 
further decided to include only the longitudinal 
sub study due to inaccurate data reporting in the 
cross-sectional sub study.9 The total number of 
subjects in the included studies was 100,725. 
The flowchart showed the process of studies 
selection (Figure 1).
Study Characteristics
The studies were published between 2009 
and 2015, and the characteristics of which are 
summarized in Table 1. Studies were done in 
various countries, including China (n=4)9,15,16,21, 
Korea (n=4)14,19,21,22, Japan (n=1)19, India (n=1)25, 
53 studies identified in literature search
(50 in Pubmed, 3 in Cochrane )
Potentially relevant studies for
further evaluation
(n=19)
Studies excluded after screening titles
and abstracts (n=34)
Studies included in meta -analysis
(n=11)
 Not reporting adjusted odds
ratio (n=2)
 Small sample size (n=2 )
 Not excluding subject with
hepatitis C virus infection
(n=1)
Potentially relevant studies met
inclusion criteria
(n=14)
 Quality issue (n=2)
 Using the same subjects (n=1)
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Figure 1. Flow chart of study selection process
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and the USA (n=1).23 There were six cross 
sectional studies, three prospective studies, and 
two retrospective studies. Three studies had non-
diabetic subjects only20,22,23, one study separated 
the subjects into obese and non-obese19, 1 
study  included non-obese, non-diabetic, non 
hypertensive, non dyslipidemia subjects only.25
Meta-analysis Result
The total event of NAFLD was 18,303. 
The pooled adjusted OR for NAFLD from 11 
studies was 1.92 (95% CI: 1.66-2.23; p<0.00001) 
(Figure 2) We performed subgroup analysis 
based on study design, showing pooled adjusted 
OR was 1.55 (95% CI: 1.23-1.96; p<0.0002) in 
three prospective studies9,15,22, 2.06 (95% CI: 
1.70-2.51; p<0.00001) in six cross sectional 
studies14,16,19,21,23,25, and 1.93 (95% CI: 1.49-2.49; 
p<0.00001) in two retrospective studies.8,20 
(Figure 2)
In subgroup analysis based on gender, the 
pooled adjusted OR was 1.52 (95% CI: 1.35-1.72; 
p<0.00001) in men8,9,14,19,22,23,25 and 1.93 (95% 
CI: 1.67-2.23; p<0.00001) in women.8,9,14,19,23,25 
Moderate heterogeneity (I2=47%) was found 
in men group but no heterogeneity (I2=0%) 
in women group. (Figure 3) Four studies in 
non-diabetic subjects20,22,23,25 and two studies 
in non-obese subjects19,25 revealed statistically 
significant adjusted OR (OR 1.56; 95% CI: 1.34-
1.82; p<0.0001 and OR 1.73; 95% CI: 1.36-2.2; 
p<0.0001, respectively) with no substantial 
heterogeneity (I2=28% in both subgroup). 
(Figure 4 and Figure 5) 
For the overall 11 studies, no evidence of 
publication bias was observed in the funnel plot 
(Figure 6).
DISCUSSION
In our meta-analysis of 11 studies, we found 
a significant association between serum uric acid 
and NAFLD. The risk of NAFLD was increased 
almost 2-fold in the highest serum uric acid 
Figure 2. Forest plot describing association between serum uric acid and NAFLD in overall studies and subgroup analysis 
based on study method
Guntur Darmawan                                                                                                                 Acta Med Indones-Indones J Intern Med
144
Figure 3. Forest plot describing association between serum uric acid and NAFLD based on gender
Figure 4. Forest plot describing association between serum uric acid and NAFLD in non-diabetic subjects
Figure 5. Forest plot describing association between serum uric acid and NAFLD in non-obese subjects
group compared to the lowest group. This finding 
was in line with previous meta-analysis study 
by Liu, showing a dose-response relationship 
of serum uric acid with incidence of NAFLD 
in two prospective studies.27 Although the 
pathogenesis is still not fully understood, several 
mechanisms are hypothesized to explain the 
relationship. Uric acid stimulated inflammation 
through production of p38 mitogen-activated 
protein kinases (MAPK), cyclooxygenase-2 
(COX-2), chemokinemonocyte chemoattractant 
protein-1. Moreover, serum uric acid within 
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the normal range correlated positively with 
interleukin-18 (IL-18), IL-6, and tumor necrosis 
factor-α (TNF-α). It also induced oxidative 
stress in adipocytes and vascular cells. Uric acid 
amplified the lipogenic effects of fructose by 
increasing ketohexokinase (KHK) expression 
which resulted in triglycerides accumulation 
in hepatocytes. The co-presence of insulin 
resistance in NAFLD might increase the serum 
uric acid through reduction of uric acid clearance 
in the renal proximal tubule.17,28
We did subgroup analyses to explore the 
association within the similar study design, 
gender and subject characteristics.Cross sectional 
studies showed significant association between 
serum uric acid and NAFLD. Longitudinal 
studies, intended to further investigate the causal 
relationship, also revealed significant association, 
with better value in heterogeneity. Men and 
women have different serum uric acid levels, 
influenced by the uricosuric effect of estrogens. 
Our study revealed that the association between 
serum uric acid and NAFLD were significant in 
both genders, with higher risk in women. The 
higher impact in women was in accordance 
with other studies observing the relationship 
between gender-specific hyperuricemia and 
the development of cardiovascular metabolic 
disorders.8,29-31 Although it is still cannot be 
fully explained, the difference in sex hormones, 
gender-specific effects of uric acid production, 
life style are proposed to be the underlying 
mechanism.9,30
Some of the well known risk factors for 
NAFLD are diabetes and obesity.3,7,32,33 Although 
there were adjustment for body mass index 
and blood glucose in the included studies, we 
performed two subgroup analyses evaluating 
studies using non-diabetic subjects and studies 
using non-obese subjects. Analyses of 4 studies in 
non-diabetic subjects using different approaches 
(retrospective, prospective, and cross-sectional) 
revealed a significant association with moderately 
low heterogeneity. Similar result was found in 
analyses of 2 studies in non-obese subjects. 
These, strengthen the relationship between uric 
acid and NAFLD regardless diabetes or obesity 
status.
In addition, 2 studies evaluated the 
relationship between serum uric acid levels and 
severity of hepatic steatosis by ultrasonography 
examination.23,25 Both of the studies showed 
increasing severity of NAFLD in line with 
increased serum uric acid levels. This finding 
was in accordance with study by Lin, showing 
that liver fat content accumulation was associated 
with elevated serum uric acid.34
The large number of subjects from different 
countries included in the meta-analysis was the 
strength of our study. Other strength was we 
separately evaluated the association between 
serum uric acid levels and NAFLD in based 
on study design and subjects’ characteristic. 
The significant association between serum uric 
acid levels and NAFLD as shown in our study, 
might bring a new insight in clinical practice as a 
physician. First, although the role was not totally 
clear (e.g. as marker or etiology), increased serum 
uric acid may bring the physician to screen for 
the risk of NAFLD. Second, there is a potential 
therapeutic role of xanthin oxidase inhibitor, 
such as allopurinol, in NAFLD. Inhibition of 
xanthin oxidase would lower KHK levels and 
amelioratethe lipogenic effects of fructose in the 
liver, as shown in animal study by Lanaspa.28
Several limitations in our study should 
be mentioned. First, almost all subjects were 
health check-up patients; therefore, selection 
bias might be present in the study since subjects 
participating in the study would be more health-
conscious, having less severe disease than 
general population in community. Nonetheless, 
it would just underestimate the observed 
association between serum uric acid and 
Figure 6. Funnel plot
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NAFLD. Secondly, there was no adjustment for 
dietary factors, such as meat and fructose intake 
which might influence serum uric acid levels 
and NAFLD. Thirdly, since alcohol intake data 
was taken based on self-report questionnaire, it 
can underestimate the exact amount of alcohol 
consumed. Fourthly, NAFLD was determined 
by ultrasonography examination in all included 
studies with no histologic confirmation of fatty 
liver. None of the studies performed either liver 
biopsy or liver fibroscan examination. Although 
liver ultrasonography is not the gold standard, it 
is the first-line imaging technique for NAFLD. 
Liver ultransonography is non-invasive, safe, has 
an acceptable accuracy, and able to evaluate the 
severity of fatty liver either qualitatively or semi-
quantitatively.39 Lastly, there is a need to consider 
the menstrual cycle phase in premenopausal 
women since serum uric acid levels may varies 
throughout the menstrual cycle.40
Further studies on community based 
subjects with prospective design are needed 
to demonstrate clearly the causal relationship 
between serum uric acid levels and NAFLD. 
Moreover, prospective studies using xanthine 
oxidase inhibitor as a potential treatment of 
NAFLD deserve should be conducted.
CONCLUSION
Our report showed an association between 
serum uric acid levels and NAFLD. This finding 
brings new insight into uric acid in clinical 
practice. Increase serum uric acid levels might 
serve as a trigger for physician to screen for 
NAFLD.
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